

## **PROJECT DETAILS:**

GRANT AGREEMENT NUMBER PROJECT FULL TITLE

TOPIC START DATE OF THE PROJECT DURATION PROJECT COORDINATOR

EU CONTRIBUTION PROJECT WEBSITE

101095653

BIOmarker based diagnostic TOOLkit to personalize pharmacological approaches in congestive heart failure.

HORIZON-HLTH-2022-TOOL-11-01

1 October 2023 60 Months

Dr. Luciano Potena | IRCCS AZIENDA OSPEDALIERO

UNIVERSITARIA DI BOLOGNA RCCS

9.600.663,00 Euro

https://www.biotool-chf.eu/

#### **PARTNERS**

*	Assistance Publique Hopitaux de Paris	France
+	Ethniko Kai Kapodistriako Panepistimio Athinon	Greece
-	Univerzitetni Klinicni Center Ljubljana	Slovenia
-	Institut de Investigacio en Ciencies de la Salut Germans Trias i Pujol	Spain
-	Fundacion para la Investigacion del Hospital Clinico de la Comunitat Valenciana	
	Fundacion Incliva	Spain
+	Katholieke Universiteit Leuven	Belgium
+	Region Hovedstaden	Denmark
-	Alma Mater Studiorum - Università di Bologna	Italy
-	Onaseio Kardiocheirourgiko Kentro	Greece
-	Institut National de la Sante et de la Recherche Medicale	France
-	Predict4Health	France
-	ECRIN European Clinical Research Infrastructure Network	France
-	Istituto Superiore di Sanità	Italy
-	Warrant Hub S.p.A	Italy
-	Universitatsklinikum SchleswigHolstein	Germany
-	Universitaet zu Luebeck	Germany
-	Associazione Italiana Scompensati Cardiaci Associazione di Promozione Sociale	Italy
-	I.M.A. Industria Macchine Automatiche S.p.A	Italy
+	Erasmus Universiteit Rotterdam	Netherlands
+	Fondazione per il Tuo Cuore Onlus	Italy
+	Fachhochschule Nordwestschweiz	Switzerland
#	Academisch Ziekenhuis Groningen	Netherlands
-	Università degli Studi di Brescia	Italy
#	Region Stockholm	Sweden



"Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them."



# The European Commission funds a breakthrough in Chronic Heart Failure Management

## BIOTOOL-CHF EU funded project kicks-off in Bologna

<u>29 January 2024, Bologna (Italy)</u> | The "BIOmarker based diagnostic TOOLkit to personalize pharmacological approaches in congestive heart failure" (BIOTOOL-CHF) project has started its journey under the HORIZON-HLTH-2022-TOOL-11-01 topic. With a duration of 60 months, the project is coordinated by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA and boasts a total cost of 9,600,663.00 Euros, funded by the European Union.

The core objectives of BIOTOOL-CHF include the validation of qualified biomarkers estimating congestion, the definition of an artificial intelligence-based score predicting congestion and prognosis, the development of a decision-making tool for diuretic management, the creation of a Point of Care companion diagnostic (CD) for assessing biomarkers concentrations, and the establishment of a Strategy plan for industrial development and market access of the CD. This holistic approach aims to revolutionize the management of heart failure with reduced ejection fraction (HFrEF), offering a more efficient and personalized strategy for patients through innovative tools and digital solutions.

The substantial funding from the European Union for the BIOTOOL-CHF project reflects the critical importance of addressing the challenges posed by heart failure with reduced ejection fraction (HFrEF). With approximately 6.5 million Europeans affected by this condition, leading to high healthcare costs and significant mortality rates, the project's objectives align with the pressing need for innovative solutions. The EU's investment underscores its commitment to advancing medical research, personalized healthcare, and the development of tools that can significantly impact patient outcomes.

The project aligns with the overarching goal of providing regulatory agencies and scientific societies with a framework for disseminating recommendations, thus enabling the enhanced use of existing pharmaceuticals and facilitating the achievement of target guideline-directed medical therapy for HFrEF patients.

Through the combined work of over twenty hospitals, universities, and research centers spanning Italy, Germany, France, the Netherlands, Belgium, Greece, Slovenia, Spain, Denmark, Switzerland, and Sweden, the project seeks to improve the management of congestion linked to heart failure by implementing a more effective administration of diuretic medications.

### CONTACTS:

Luciano Potena (IRCCS AOU BO) | Project Coordinator luciano.potena@aosp.bo.it Isella Vicini (Warrant Hub S.p.A.) | Dissemination Manager isella.vicini@warranthub.it

